[Selon ce message de e-drug, Sabine Kopp du département Médicaments Essentiels et Politiques pharmaceutiques de l'OMS, vous invite à participer à cette réunion publique qui se tiendra à Genève le 15 juillet 2011 en vous inscrivant par mail à cette adresse: BonnyW@who.int
CB]
-----Message d'origine-----
la part de Kopp, Sabine
Envoyé : jeudi 23 juin 2011 16:34
WHOIP
E-DRUG: Still possible to join!! ONE-DAY PUBLIC MEETING ON THE WHO IP
-----------------------------------------------------------
{If you are interested, please email BonnyW@who.int. DO NOT CLICK REPLY]
It is still possible to join the
ONE-DAY PUBLIC MEETING ON THE WHO INTERNATIONAL PHARMACOPOEIA,
World Health Headquarters, Geneva, 15 July 2011
We are pleased to announce that the Medicines Quality Assurance Programme of
the World Health Organization (WHO) is proposing to hold a one-day public
meeting on the WHO normative work in the area of medicines quality control.
This is aimed predominantly at explaining to interested parties, including
pharmaceutical manufacturers, the nature of The International Pharmacopoeia
and will provide an opportunity to ask questions they would like answered on
The International Pharmacopoeia.
The briefing will include the mechanics - how monographs, including those
for antimalarials, are developed etc. - together with explanations of
pharmacopoeial approach/policy on a variety of issues and of its role within
WHO's overall Quality Assurance activities.
This meeting will also explain how the WHO Medicines Quality Assurance
Programme works with The International Pharmacopoeia, how manufacturers
could participate in that work and how we could work together efficiently to
provide appropriate international testing specifications as an important
tool to enable supply of quality medicines to patients.
The briefing should take place on Friday, 15 July 2011 (from 10.00 to 12:00;
and 14:00 to 16:30) at WHO headquarters in Geneva and we have pleasure in
inviting a representative from your association/company to attend. We do
regret, however, that it will not be possible for the World Health
Organization to meet any expenses relating to this attendance.
We will have to adopt the policy of "first come-first served" as space for
attendance at the briefing will be limited, and we thank you for your
understanding.
We look forward to receiving your reply; please send to: BonnyW@who.int.
Lembit Rägo, MD, PhD
Coordinator
Quality Assurance and Safety: Medicines
Department of Essential Medicines and Pharmaceutical Policies
World Health Organization
Geneva
"Kopp, Sabine" <kopps@who.int>